---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-26-039691"
form_type: "8-K/A"
ticker: "OSRH"
cik: "0001840425"
company_name: "OSR Holdings, Inc."
filed_at: "2026-04-03T23:59:59+00:00"
generated_at: "2026-05-15T07:39:40.814041+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.9
calibrated_materiality_score: 0.9
confidence: "high"
source: SEC EDGAR
---

# OSR Holdings (OSRH) Enters Binding Term Sheet for VXM01 License with BCM Europe; $815M Milestones, $30M Facility

## Summary
- The binding term sheet grants BCM Europe exclusive worldwide rights to VXM01, with OSR Holdings providing up to $30M development financing to Vaximm AG.
- BCM Europe Fund will pay up to $815M in milestone payments directly to OSR Holdings upon clinical and regulatory achievements.
- OSR Holdings retains an equity option to issue up to $15M of common stock at $10/share (premium to market) to BCME Fund.
- Royalties from an ultimate licensee will pass through to OSR Holdings after recovery of a negative milestone delta and minimum preferred return.
- The transaction is a related-party deal requiring an independent fairness opinion; the term sheet supersedes a prior January 2026 term sheet.

## SEC filing metadata
- accession: 0001213900-26-039691
- form_type: 8-K/A
- ticker: OSRH
- cik: 0001840425
- company_name: OSR Holdings, Inc.
- filed_at: 2026-04-03T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.9
- calibrated_materiality_score: 0.9
- confidence: high
- sec_items: 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1840425/000121390026039691/0001213900-26-039691-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1840425/000121390026039691/ea0285057-8ka1_osr.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-26-039691
- JSON: https://secwatch.observer/filing/0001213900-26-039691.json
- Plain text: https://secwatch.observer/filing/0001213900-26-039691.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.